Business
Guardant Health to present data at San Antonio Breast Cancer Symposium demonstrating utility of liquid biopsy in biomarker identification, therapy selection and residual disease detection
Spotlight sessions highlight role of Guardant blood tests in tissue-free detection of minimal residual disease and predictive impact of ctDNA genomic
About this update from Guardant Health, Inc.
[{"type":"text","content":"\n\nSpotlight sessions highlight role of Guardant blood tests in tissue-free detection of minimal residual disease and predictive impact of ctDNA genomic profiling\n\n\n\nMRD study found ctDNA detection after adjuvant therapy using Guardant Reveal™ was prognostic for distant recurrence of cancer nearly eight months before detected via standard of care surveillance\n\n\n\n PALO ALTO, Calif.--(BUSINESS WIRE)--\nGuardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, will present data showing the utility of liquid biopsy tests in the management of breast cancer patients at the San Antonio Breast Cancer Symposium, December 5-9 in San Antonio, Texas. Highlights of the eight poster presentations include the use of blood-based testing to identify actionable biomarkers and predict therapy response in advanced breast cancer, and to detect residual disease and predict recurrence in patients with early-stage breast cancer.\n\n\n“We look forward to sharing new data in San Antonio demonstrating the utility of liquid biopsy in advancing the practice of precision oncology for patients with breast cancer,” said Craig Eagle, Guardant Health chief medical officer. “The presentations will show how comprehensive genomic profiling and residual disease detection using blood-based testing provide critical insights to help oncologists develop personalized treatment plans that can improve patient outcomes.”\n\n\nTwo studies were selected for spotlight discussions:\n\n\n\nThe PlasmaMATCH study assessed the feasibility of ctDNA genomic profiling for actionable biomarker detection and therapy selection in patients with advanced breast cancer. This research explores the use of ctDNA at multiple points in time to predict therapy response in patients on targeted therapy, including establishing thresholds that best predict clinical outcomes. Study results show the use of longitudinal sampling and ctDNA assessment may help in understanding, predicting and preparing for clinical outcomes in patients receiving systemic therapy.\n\n\n\n\nIn a large feasibility study of over 300 patients with early-stage breast cancer, samples were collected about two years after curative-intent adjuvant chemotherapy and tested with Guardant Reveal, using epigenomic technology to assess for the presence of ctDNA. The study found ctDNA detection after adjuvant ther...